Clinical Trial Update: Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors [Phase 4]

View source ↗

Summary

Phase 4 trial update for everolimus (Certican) in kidney transplant recipients from HLA-identical living donors. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Certican (everolimus)

Snippet

Sponsor: Hospital do Rim e Hipertensão | Conditions: Kidney Transplantation | Phase 4 | Status: COMPLETED